| 摘要 |
<p>The present invention demonstrates the differential sensitivity of PBLs from lung cancer patients and healthy controls to NNK-induced genetic damage. The data provide convincing evidence that the preferred CBMN assay is a robust test for detection of this sensitivity and yields results that are a good predictor of, for example, lung cancer risk. The simplicity, rapidity, and sensitivity of the CBMN test make it a valuable tool for screening and, for example, prioritizing potential cases for early detection of the disease.</p> |
| 申请人 |
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM;EL-ZEIN, RANDA, A.;SCHABATH, MATTHEW, B.;ETZEL, CAROL, J.;LOPEZ, MIRTHA, S.;SPITZ, MARGARET, R. |
发明人 |
EL-ZEIN, RANDA, A.;SCHABATH, MATTHEW, B.;ETZEL, CAROL, J.;LOPEZ, MIRTHA, S.;SPITZ, MARGARET, R. |
